Antibody-drug conjugates: an emerging concept in cancer therapy.
about
Linkers Having a Crucial Role in Antibody-Drug ConjugatesMethods to Design and Synthesize Antibody-Drug Conjugates (ADCs)Capturing Biological Activity in Natural Product Fragments by Chemical SynthesisEnzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapyTargeted Delivery of Proteasome Inhibitors to Somatostatin-Receptor-Expressing Cancer Cells by Octreotide ConjugationAdvances in Antibody DesignStrain Prioritization and Genome Mining for Enediyne Natural ProductsChemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug ConjugatesCurrent Status: Site-Specific Antibody Drug ConjugatesBioconjugation of therapeutic proteins and enzymes using the expanded set of genetically encoded amino acids.In Vivo Activation of Duocarmycin-Antibody Conjugates by Near-Infrared LightSynthesis and Cytotoxicity Evaluation of C4- and C5-Modified Analogues of the α,β-Unsaturated Lactone of PironetinState-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicinesSolid-phase bioconjugation of heterobifunctional adaptors for versatile assembly of bispecific targeting ligands.Improving the serum stability of site-specific antibody conjugates with sulfone linkers.Synthetic aptamer-polymer hybrid constructs for programmed drug delivery into specific target cellsNucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicineSite-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug developmentCancer stratification by molecular imaging.Methods to Make Homogenous Antibody Drug Conjugates.Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.Enzymatic functionalization of a nanobody using protein insertion technology.Translocation of Non-Canonical Polypeptides into Cells Using Protective AntigenMicroscale screening of antibody libraries as maytansinoid antibody-drug conjugates.A platform for constructing, evaluating, and screening bioconjugates on the yeast surface.Intracellular GSH-activated galactoside photosensitizers for targeted photodynamic therapy and chemotherapy.Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.Near-IR Light-Mediated Cleavage of Antibody-Drug Conjugates Using Cyanine Photocages.Synthetically Modified Viral Capsids as Versatile Carriers for Use in Antibody-Based Cell Targeting.Organometallic palladium reagents for cysteine bioconjugationA "methyl extension" strategy for polyketide natural product linker site validation and its application to dictyostatin.Super enhanced permeability and retention (SUPR) effects in tumors following near infrared photoimmunotherapy.Antibody Therapeutics in Oncology.Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.Serum Stability and Affinity Optimization of an M2 Macrophage-Targeting Peptide (M2pep).Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.Photonanomedicine: a convergence of photodynamic therapy and nanotechnology.Discovery and characterization of hydroxylysine in recombinant monoclonal antibodies.Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagentsMirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
P2860
Q26752763-1CA63EC0-2EEE-44B4-B86E-6A27A5F03D4BQ26768654-1F34E9F1-A937-4CDC-BCC2-CB6AB6BCBEAEQ26772873-BF201B60-979C-45FD-8323-EF14C28C995BQ27701980-AB929323-A854-4245-B56C-86B24CEC69A7Q27702302-CEB3BB1E-540B-4F11-BCE4-BF0F52037FCFQ28817608-24371DE3-A782-4CA8-8C8A-BFFAE9CF8884Q28818668-F44DB899-CCBB-4673-AD63-FF73F769ED6DQ28828981-5503B3EC-66B0-4FC8-9C14-47AE007AF7E8Q28829290-5951FB66-10AD-4780-8BFB-0301F37A219DQ30279245-D9B5E7E9-4AE2-461C-A439-2A05252A499DQ33612435-50AF5C8D-E07C-4EEB-8337-1C8DC6906D49Q33628649-AE42F1B8-F744-40B5-A94C-C9AE661153C3Q34045119-D8D5FCC2-97CF-4FDE-81C1-C82DC1255B98Q34074743-0901287B-5C94-4D1C-AB0A-FB2D83B96255Q34074771-704ACC4E-BC65-4C6A-9CD4-1C2C859C1809Q34408096-E882C8BC-37E7-4A51-B355-4328BF0B5650Q34698624-0B5C7F7A-8644-494D-A119-E8A7E3E6B494Q35105725-4CD30E15-1F34-4C62-8DD6-52385F425B18Q35380664-031C2937-ED30-48E7-B9A6-E7B2B4F7CFABQ35523479-3029E518-B685-43C8-8955-854814864EF1Q35542237-F8535EFA-7B3E-4337-BF84-595BBC17F9FDQ35597176-4A794E1C-BFAD-4644-9456-B650F327680BQ35856399-0E31DEAB-A698-4132-B695-BF2362A312D0Q35890716-93AD90EA-FD5F-4C59-ABA4-CF047C52A69CQ36102147-E018F1BE-C91E-4C6B-9FAD-7D4D405F75D6Q36220307-ABE57B06-FC0E-4B1D-860D-AF70389BAE3AQ36378949-FAA39200-A31E-46B6-80A6-FEC3D7191D7DQ36551221-8C75A65B-A33A-44EF-AD79-81599A23EF71Q36592213-25B96822-4CE4-4881-8854-1CDC5C63290BQ36733631-C818EC7A-9062-4619-A685-C04BE0BD1942Q36738065-5EBB4F13-3A07-4BCF-8A50-EA5C8600B654Q36777569-63B5D217-FE0D-4675-AB02-4CB918EB93EDQ36791878-F5FE09C8-141D-481C-B0DF-E71D12667A2AQ36820693-70080040-7D15-4A79-AABC-DFFCBE239659Q37045947-9F5EBCE0-EA16-44BB-8E79-81E39A99CDB9Q37066113-908CD51C-542C-4CB9-989C-E2846E21F8A8Q37115994-74178F47-1C43-4C66-97FE-6ED837C22056Q37138489-7B809AF1-76C1-419C-A54C-7EE962A470A7Q37393159-101B6506-3460-4456-B351-42697F46BDACQ37447340-B017F0B1-26CE-4160-BC95-80DFDD28B51A
P2860
Antibody-drug conjugates: an emerging concept in cancer therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antibody-drug conjugates: an emerging concept in cancer therapy.
@en
type
label
Antibody-drug conjugates: an emerging concept in cancer therapy.
@en
prefLabel
Antibody-drug conjugates: an emerging concept in cancer therapy.
@en
P2093
P356
P1476
Antibody-drug conjugates: an emerging concept in cancer therapy.
@en
P2093
Michael L Miller
Ravi V J Chari
Wayne C Widdison
P304
P356
10.1002/ANIE.201307628
P407
P577
2014-02-20T00:00:00Z